Clinical Trials on Newly Diagnosed Multiple Myeloma (NDMM) in United States

Total 2163 results

National Cancer Institute (NCI)

Recruiting

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)

United States
Jacob Laubach, MD
Sanofi

Recruiting

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Multiple Myeloma | Autologous Stem Cell Transplant | Newly Diagnosed Multiple Myeloma (NDMM)

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center

Active, not recruiting

Smoking Cessation Intervention for Cancer Patients

Newly Diagnosed Cancer Patients

United States
Larysa Sanchez
Janssen, LP

Recruiting

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Newly Diagnosed Multiple Myeloma

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Multiple Myeloma and Exercise

Newly Diagnosed Multiple Myeloma

United States
Oncotherapeutics
Takeda

Terminated

Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

Newly Diagnosed Multiple Myeloma

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Multiple Myeloma | Newly Diagnosed Multiple Myeloma | Autologous Stem Cell Transplantation

United States
Bristol-Myers Squibb
Abbott

Terminated

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Newly Diagnosed, Previously Untreated Multiple Myeloma

United States, Poland, Italy, Greece
Freenome Holdings Inc.

Recruiting

The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening

Newly-diagnosed Cancers | Non-cancer Controls

United States
Arog Pharmaceuticals, Inc.

Completed

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

Newly Diagnosed AML With FLT3 Activating Mutations

United States
Celgene Corporation

Completed

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

Newly Diagnosed Multiple Myeloma

Spain, Netherlands, Austria, Australia, Italy, Russian Federation, United Kingdom, Israel, Belgium, Greece, Germany, Poland, Turkey, France, Denmark, Czech Republic, Belarus, Georgia, Ireland, Sweden, Switzerland, Ukraine
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)

Recruiting

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Recurrent Glioblastoma | Newly Diagnosed Glioblastoma | Recurrent Gliosarcoma | Recurrent Astrocytoma, Grade IV | Newly Diagnosed Gliosarcoma | Newly Diagnosed Astrocytoma, Grade IV

United States
Arog Pharmaceuticals, Inc.

Recruiting

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Newly Diagnosed FLT3 Mutated AML

United States
Imperial College London
Novartis Pharmaceuticals

Completed

Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment

Chronic Myeloid Leukemia | Newly Diagnosed

United Kingdom
University of Utah

Completed

Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance (POWER PIINC)

Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer

United States
Weill Medical College of Cornell University

Terminated

Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed Breast Cancer

Newly Diagnosed Breast Cancer

United States
James Felker
Connor's Cure; Ellie Kavalieros Fund; Translational Brain Tumor Research Fund

Active, not recruiting

A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas

Newly Diagnosed Pediatric Pontine Glioma | Newly Diagnosed Pediatric High Grade Glioma | Recurrent Pediatric High Grade Glioma | Recurrent Pediatric Low Grade Glioma

United States
Wake Forest University

Terminated

A 5 Year Follow-up on Newly Diagnosed Breast Cancer Patients

Newly Diagnosed Breast Cancer

United States
University of Pennsylvania

Recruiting

CART-38 in Adult AML and MM Patients

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM)

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

Acute Leukemia | Newly Diagnosed | Relapsed

United States
Swedish Medical Center

Recruiting

Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

Newly Diagnosed Glioblastoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Accelerate Brain Cancer Cure

Completed

Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide (Mebendazole)

Newly Diagnosed High-Grade Glioma

United States
St. Joseph's Hospital and Medical Center, Phoenix
Blue Earth Diagnostics; Barrow Neurological Foundation; Arizona Biomedical Research...

Recruiting

Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma

Newly Diagnosed Glioblastoma

United States
Stanford University
NovoCure Ltd.

Recruiting

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

Glioblastoma | Newly Diagnosed Glioblastoma

United States
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

Leukemia, Myeloid, Acute | Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS)

Spain, United States, France, Korea, Republic of, Taiwan, Australia, Canada, Germany, China, Italy, Austria, Czechia, Poland, Japan, United Kingdom, Russian Federation, Netherlands, Brazil, Israel, Mexico
National Cancer Institute (NCI)

Active, not recruiting

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Glioblastoma | Gliosarcoma | Newly Diagnosed

United States
University of Utah

Completed

Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED) (D-TERMINED)

Newly Diagnosed High Grade Glioma

United States
Kentuckiana Cancer Institute
Eisai Inc.

Unknown

Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma

Newly Diagnosed Supratentorial Malignant Glioma

United States
Darell Bigner
Rockefeller University

Recruiting

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Newly Diagnosed MGMT Unmethylated Glioblastoma

United States
City of Hope Medical Center

Completed

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Smoldering Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
City of Hope Medical Center

Completed

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Saint John's Cancer Institute

Completed

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Newly Diagnosed High Grade Glioma

United States
Mayo Clinic

Completed

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Multiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Indiana University School of Medicine
Roche Pharma AG; Facet Biotech; Pescovitz, Mark D., M.D.

Completed

Prevention of Diabetes Progression Trial (PDPT)

Newly Diagnosed With Type 1 Diabetes

United States
Benovus Bio, Inc.

Unknown

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (BBMPI03)

Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Multiple Myeloma (MM) | Smoldering Multiple Myeloma (sMM)

United States
Jonsson Comprehensive Cancer Center
GlaxoSmithKline; Novartis

Completed

Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

Newly Diagnosed Glioblastoma Multiforme

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
NYU Langone Health
National Cancer Institute (NCI)

Terminated

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Thrombocytopenia | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States

Clinical Trials on Newly Diagnosed Multiple Myeloma (NDMM) in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations